Phase I Study to Evaluate the Effect of Hepatic Impairment on Pharmacokinetics and Safety of Tegoprazan, a Potassium Competitive Acid Blocker

Category Primary study
JournalAdv. Ther.
Year 2025
This article has no abstract
Epistemonikos ID: c5d8474bcb5dd06ab3ea8429426caf573647452c
First added on: Feb 26, 2025